Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation Therapy + Immunotherapy in Metastatic NSCLC
NCT03035890Completed
- Sponsor
- West Virginia University
- Start
- Jan 2017
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab, pembrolizumab and atezolizumab in non-small cell lung cancer (NSCLC), sponsored by West Virginia University. Primary endpoint: Time to Best Overall Response at 2 years. Started Jan 2017; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03035890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03035890.